Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An update from NurExone Biologic ( (TSE:NRX) ) is now available.
NurExone Biologic Inc. has appointed Jacob Licht as CEO of Exo-Top Inc., a subsidiary focused on exosome manufacturing in the U.S., to enhance its global supply chain and commercialization strategy. This move is expected to scale manufacturing capacity and support clinical trials, aligning with the company’s financial strategy to expand in North America. Additionally, the company has completed its continuance into Ontario, which aligns with its strategic growth initiatives.
More about NurExone Biologic
NurExone Biologic Inc. is a biotechnology company listed on the TSX Venture Exchange, OTCQB, and Frankfurt, focusing on developing regenerative exosome-based therapies for central nervous system injuries. Their lead product, ExoPTEN, has shown strong preclinical data for treating acute spinal cord and optic nerve injuries, targeting multi-billion-dollar markets. The company is also working towards clinical trials in the U.S. and Europe and offers solutions for quality exosomes and targeted delivery systems.
YTD Price Performance: 11.48%
Average Trading Volume: 33,990
Technical Sentiment Signal: Sell
Current Market Cap: C$40.36M
For detailed information about NRX stock, go to TipRanks’ Stock Analysis page.